Skip to main content
Premium Trial:

Request an Annual Quote

Precipio Quantitative BCR-ABL 2.0 Panel

Precipio has launched its Quantitative BCR-ABL 2.0 panel for confirming a chronic myeloid leukemia (CML) diagnosis. According to the New Haven, Connecticut-based firm, CML patients have cells containing the BCR-ABL1 gene, which creates a hybrid protein resulting in uncontrolled cell division and genomic instability. The presence of the gene confirms CML diagnosis and can be used to monitor patients and their response to various therapies. The test provides quantitative coverage of four clinically relevant breakpoints, p.190, p.210, p.203, and p.230, and the panel comes with automated analysis software, Precipio said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.